Prognosis
Gates Research Institute to Develop Glaxo’s Promising TB Vaccine
A doctor checks the chest X-ray of a patient in the tuberculosis department of a hospital in Hyderabad.
Photographer: Noah Seelam/AFP via Getty Images
This article is for subscribers only.
GlaxoSmithKline Plc licensed a promising vaccine against tuberculosis to the Bill & Melinda Gates Medical Research Institute in a move the drugmaker said will help bring prevention of the deadly disease to poor countries.
The Gates group will lead development of the vaccine candidate and sponsor future clinical tests, London-based Glaxo said in an emailed statement. Financial terms of the agreement weren’t provided.